Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: A multicenter, randomized, double-blind, controlled trial

Journal of Hypertension

Volumn 35, Issue 7, 2017, Pages 1481-1495

  Mourad, Jean Jacques ^a   Amodeo, Celso ^b   De Champvallins, Martine ^c   Brzozowska Villatte, Romualda ^c   Asmar, Roland ^d  

^a AVICENNE HOSPITAL   (France)

^b Instituto de Cardiologia Dante Pazzanese   (Brazil)

^c IRIS Institut de Recherches Internationales Servier   (France)

^d Foundation Medical Research Institute   (France)

Author keywords

amlodipine; hypertension; indapamide; perindopril; single pill combination

Indexed keywords

AMLODIPINE PLUS INDAPAMIDE PLUS PERINDOPRIL; ANTIHYPERTENSIVE AGENT; PERINDOPRIL PLUS LINDAPAMIDE; UNCLASSIFIED DRUG; URIC ACID; AMLODIPINE; INDAPAMIDE; PERINDOPRIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HOME MONITORING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERURICEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; WHITE COAT HYPERTENSION; AGED; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESSENTIAL HYPERTENSION; FEMALE; HUMANS; INDAPAMIDE; MALE; MIDDLE AGED; PERINDOPRIL; TREATMENT OUTCOME;

EID: 85015665217     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001359     Document Type: Article

References (69)

1. World Health Organization. World health statistics 2015. Geneva, Switzerland: WHO Press. Available from: http://reliefweb.int/sites/ reliefweb.int/files/resources/9789240694439-eng.pdf. [Accessed 26 July 2016]
2. Campbell NR, Khalsa T , Lackland DT, Niebylski ML, Nilsson PM, Redburn KA, Orias M, Zhang XH, Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Touyz RM, Wang JG, Weber MA; World Stroke Organization; International Diabetes Federation; International Council of Cardiovascular Prevention and Rehabilitation; International Society of Nephrology. High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. J Clin Hypertens (Greenwich) 2016; 18:714-717
3. Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Clin Hypertens (Greenwich) 2011; 13:146-154
4. Bramlage P, Bohm M, Volpe M, Khan BV, Paar WD, Tebbe U, Thoenes M. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) 2010; 12:666-677
5. Guo F, He D, Zhang W, Walton RG. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol 2012; 60:599-606
6. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al., Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011; 377:568-577
7. WHO-ISH. 2003 World Health Organization /International Society of Hypertension statement on management of hypertension. J Hypertens 2003; 21:1983-1992
8. Blacher J, Halimi JM, Hanon O, Mourad JJ, Pathak A, Schnebert B, Girerd X, French Society of Hypertension. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol 2014; 28:1-9
9. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520
10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. Guidelines for the Management of Arterial Hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357
11. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J 2016; 37:2315-2381
12. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32:3-15
13. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed dose combinations of antihypertensive agents. A metaanalysis. Hypertension 2010; 55:399-407
14. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719
15. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12:243-249
16. Xie L, Frech-Tamas F, Marrett E, Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double-and triple-pill combination therapy. Curr Med Res Opin 2014; 30:2415-2422
17. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618
18. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15
19. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs. individual component regimens. J Med Econ 2012; 15:897-905
20. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG. Evaluation of compliance and healthcare utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 2010; 26:2065-2076
21. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. The Cycle Repeats. Drugs 2002; 62:443-462
22. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC, for the Enalapril-Felodipine ER Factorial Study Group. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 1997; 79:431-435
23. Messerli FH, Grossman E. Pedal edema-not all dihydropyridine calcium antagonists are created equal. Am J Hypertens 2002; 15:1019-1020
24. Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW. Amlodipine and angiotensin converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomised control trials. Blood Press Monit 2010; 15:195-204
25. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blockerassociated peripheral edema. Am J Med 2011; 124:128-135
26. Kaplan NM,. Treatment of hypertension: drug therapy-diuretics, 8th ed. Lippincott Williams and Wilkins; 2002; pp. 241-252
27. Liu L. 2010 Chinese guidelines for the management of hypertension. Chin J Cardiol 2011; 39:579-616
28. Malachias MVB, Souza WKSB, Plavnik FL, Rodrigues CIS, Brandao AA, et al., Sociedade Brasileira de Cardiologia (SBC). 7a Diretriz Brasileira de Hipertensao Arterial [7th Brazilian Guideline of Arterial Hypertension]. Arq Bras Cardiol 2016; 107 (3 supl 3):1-83
29. Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like diuretics: a meta-analysis. Am J Hypertens 2015; 28:1453-1463
30. Kaplan NM. Indapamide is it the better diuretic for hypertension? Hypertension 2015; 65:983-984
31. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analysis of randomized trials. J Am Coll Cardiol 2011; 57:590-600
32. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone antihypertensive and metabolic effects. Hypertension 2015; 65:1041-1046
33. NICE-Clinical Guidelines Hypertension: the clinical management of primary hypertension in adults-NCGC (National Clinical Guideline Centre) 127; August 2011
34. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342:d2234
35. Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014; 174:773-785
36. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322:531-536
37. Weiss W, Tolle M, Zidek W, Van Der Giet M. Validation of the mobil-OGraph: 24 h-blood pressure measurement device. Blood Pressure Monitoring 2010; 15:225-228
38. Parati G, Stergiou GS, Asmar R, Bilo G, Leeuw P, Imai Y, et al., on behalf of the ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension practice guidelines for home blood pressure monitoring [Review]. J Hum Hypertens 2010; 24:779-785
39. Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, et al., on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring [Consensus document]. J Hypertens 2014; 32:1359-1366
40. EMA guideline on clinical investigation of medicinal products in the treatment of hypertension. EMA/238/1995/rev3-2010
41. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al., American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e5105-e5126
42. Chung N, Baek S, Chen M-F, Liau C-S, Park CG, Park J, et al. 2008 Expert recommendations on the challenges of hypertension in Asia. Int J Clin Prac 2008; 62:1306-1312
43. Petrak O, Zelinka T, Š trauch B, Rosa J, Šomloova Z, Indra T, et al. Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. J Hum Hypertens 2016; 30:35-39
44. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997
45. Staessen JA, Thijis L, Fagard R, Celis H, Birkenhager WH, Bulpitt CJ, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22:847-857
46. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031
47. O'Connor PJ, Vazquez-Benitez G, Schmittdiel JA, Parker ED, Trower NK, Desai JR, et al. Benefits of early hypertension control on cardiovascular outcomes in patients with diabetes. Diabetes Care 2013; 36:322-327
48. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427-1434
49. Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ 2015; 350:h158
50. Zikmund-Fisher BJ, Hofer TP, Klamerus ML, Kerr EA. First things first: difficulty with current medications is associated with patient willingness to add new ones. NIH Public access. Patient 2009; 2:221-231
51. Stergiou GS, Baibas NM, Gantzarou AP, Skeva II, Kalkana CB, Roussias LG, Mountokalakis TD. Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy. Am J Hypertens 2002; 15:101-104
52. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure (PAMELA study). Hypertension 2006; 47:846-853
53. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156-161
54. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-1783
55. Mallion JM, Chamontin B, Asmar R, De Leeuw PW, O'Brien E, Duprez D, et al. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am J Hypertens 2004; 17:245-251
56. Nagy VL. Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination. Clin Drug Investig 2013; 33:469-476
57. EUROPA-The European trial on reduction of cardiac event with perindopril in stable coronary artery disease (investigators). Efficacy of perindopril in reduction of cardiovascular events among patientswith stable coronary artery disease: randomised double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788
58. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370:829-840
59. PATS Collaborating Group. Poststroke antihypertensive treatment study. A preliminary result (PATS Collaborating Group). Chinese Med J 1995; 108:710-717
60. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al., HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898
61. Bulpitt CJ, Beckett NS, Peters R, Leonetti G, Gergova V, Fagard R, et al. Blood pressure control in the Hypertension in the Very Elderly Trial (HYVET). J Hum Hypertens 2012; 26:157-163
62. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041
63. Dahlof B, Sever P, Poulter N, Wedel H, Beevers G, Caulfield M, et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906
64. Nedogoda S, Stojanov V. Efficacy and safety of perindopril/indapamide/ amlodipine (P/I/A) single pill versus free combination (P/I and thorn A) at the same dose in patients with uncontrolled essential hypertension. Cardiol Ther 2017 [Epub ahead of print] 8 February. http://link.springer. com/article/10.1007/s40119-017-0085-7
65. Pall D, Szanto I, Szabo Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig 2014; 34:701-708
66. Toth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs 2014; 14:137-145
67. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes And Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014; 63:259-264
68. Yamout H, Bakris GL. Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus. Hypertension 2014; 63:220-221
69. Kreutz R, Ammentorp B, Laeis P, Sierra A. Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. J Clin Hypertens 2014; 16:729-740